Randomized trial shows phage vB_KpnS_SXK7 reduces bacterial viability in Klebsiella pneumoniae, suggesting a new treatment approach.
The increasing prevalence of multidrug-resistant (MDR) Klebsiella pneumoniae necessitates alternative therapeutic strategies. Here, we isolated and characterized a lytic phage, vB_KpnS_SXK7, from hospital sewage and investigated the host’s resistance mechanism. Morphological analysis identified it as a siphovirus-type phage. It exhibited a 30-min latent period, a burst size of 270 PFU/infected cell, and stability across pH 5–12 and temperatures up to 60 °C. Host range testing against 25 K. pneumoniae strains showed that vB_KpnS_SXK7 lysed 9 strains (36%). Whole-genome sequencing revealed a 49.1-kb circular dsDNA genome lacking tRNA, virulence, or antibiotic-resistance genes, confirming its safety profile. In vitro, vB_KpnS_SXK7 reduced bacterial viability within 2 h. In a Galleria mellonella infection model, a single dose (MOI 100) rescued 80% of larvae from lethal challenge without toxicity. Genomic analysis of resistant mutant SXK7-R11 identified a single-nucleotide deletion in wzm , which encodes an ABC transporter permease essential for O-antigen assembly. This mutation impaired phage adsorption, which was restored by genetic complementation. These findings establish vB_KpnS_SXK7 as a promising preclinical candidate but highlight its vulnerability to resistance mechanisms involving O‑antigen‑associated pathways, supporting the development of phage cocktails targeting multiple receptors against MDR infections.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: